Company intelligence / Profile preview

Shanghai Epiprobe Biotechnology

Shanghai, Shanghai, Chinaepiprobe.net ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s core liquid biopsy technology enables non-invasive, highly sensitive detection of early-stage cancers by analyzing specific DNA methylation patterns in cell-free DNA. Clinical results show high sensitivity and moderate specificity in endometrial cancer screening using the PCDHGB7 marker with accuracy up to ~85%. Three products have obtained CE certification covering cervical, endometrial, and urothelial cancers.

Therapeutic areas: Oncology
Modalities: Diagnostic kit (Molecular diagnostics)Liquid biopsy technologyDNA methylation detection assayArtificial intelligence-based diagnostic algorithm
Industry: Molecular Diagnostics

Partnerships

Not explicitly listed; possible collaborations with academic institutions on biomarker validation studies.

Beyond the preview

Go deeper on Shanghai Epiprobe Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Epiprobe Biotechnology.

Explore the full profile